Chemokine levels in subretinal fluid obtained during scleral buckling surgery after rhegmatogenous retinal detachment

Investigative Ophthalmology and Visual Science

Volumn 51, Issue 8, 2010, Pages 4143-4150

  Ricker, Lukas J A G ^a,b   Kijlstra, Aize ^a   de Jager, Wilco ^c   Liem, Albert T A ^a   Hendrikse, Fred ^a   la Heij, Ellen C ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b European Graduate School For Neuroscience   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CCL18 CHEMOKINE; CHEMOKINE; CXCL9 CHEMOKINE; EOTAXIN; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 6; INTERLEUKIN 8; MACROPHAGE DERIVED CHEMOKINE; MACROPHAGE INFLAMMATORY PROTEIN 3BETA; MACROPHAGE MIGRATION INHIBITION FACTOR; MONOCYTE CHEMOTACTIC PROTEIN 1; THYMUS AND ACTIVATION REGULATED CHEMOKINE; UNCLASSIFIED DRUG; IL6 PROTEIN, HUMAN;

ADULT; AGE; AGED; ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETINA DETACHMENT; SCLERA BUCKLING PROCEDURE; SEX DIFFERENCE; SUBRETINAL FLUID; TREATMENT OUTCOME; UPREGULATION; VITREORETINOPATHY; BODY FLUID; EXUDATE; METABOLISM; MIDDLE AGED; POSTOPERATIVE COMPLICATION; RECURRENT DISEASE;

ADULT; AGED; BODY FLUIDS; CHEMOKINES; EXUDATES AND TRANSUDATES; FEMALE; HUMANS; IMMUNOASSAY; INTERLEUKIN-6; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; RECURRENCE; RETINAL DETACHMENT; SCLERAL BUCKLING; UP-REGULATION; VITREORETINOPATHY, PROLIFERATIVE;

EID: 77955901392     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.09-5057     Document Type: Article

References (52)

1. Charteris DG. Proliferative vitreoretinopathy: pathobiology, surgical management, and adjunctive treatment. Br J Ophthalmol. 1995;79:953-960.
2. Pastor JC, de la Rúa ER, Martín F. Proliferative vitreoretinopathy: risk factors and pathobiology. Prog Retin Eye Res. 2002;21:127-144.
3. Weller M, Heimann K, Wiedemann P. Demonstration of mononuclear phagocytes in a human epiretinal membrane using a mono-clonal anti-human macrophage antibody. Graefes Arch Clin Exp Ophthalmol. 1988;226:252-254.
4. Charteris DG, Hiscott P, Robey HL, Gregor ZJ, Lightman SL, Grierson I. Inflammatory cells in proliferative vitreoretinopathy subretinal membranes. Ophthalmology. 1993;100:43-46.
5. Esser P, Heimann K, Wiedemann P. Macrophages in proliferative vitreoretinopathy and proliferative diabetic retinopathy: differentiation of subpopulations. Br J Ophthalmol. 1993;77:731-733.
6. Proença R, Carvalho M, Proença D, Verissimo J, Regadas I, Travassos A. HLA antigens and lymphocytes in proliferative vitreoretinopathy. Graefes Arch Clin Exp Ophthalmol. 1994;232:25-32.
7. Baudouin C, Hofman P, Brignole F, Bayle J, Loubière R, Gastaud P. Immunocytology of cellular components in vitreous and subretinal fluid from patients with proliferative vitreoretinopathy. Ophthalmologica. 1991;203:38-46.
8. Canataroglu H, Varinli I, Ozcan AA, Canataroglu A, Doran F, Varinli S. Interleukin (IL)-6, interleukin (IL)-8 levels and cellular composition of the vitreous humor in proliferative diabetic retinopathy, proliferative vitreoretinopathy, and traumatic proliferative vitreoretinopathy. Ocul Immunol Inflamm. 2005;13:375-381.
9. Struyf S, Proost P, Van Damme J. Regulation of the immune response by the interaction of chemokines and proteases. Adv Immunol. 2003;81:1-44.
10. Wallace GR, Curnow SJ, Wloka K, Salmon M, Murray PI. The role of chemokines and their receptors in ocular disease. Prog Retin Eye Res. 2004;23:435-448.
11. Abu El-Asrar AM, Struyf S, Kangave D, Geboes K, Van Damme J. Chemokines in proliferative diabetic retinopathy and proliferative vitreoretinopathy. Eur Cytokine Netw. 2006;17:155-165.
12. Capeans C, De Rojas MV, Lojo S, Salorio MS. C-C chemokines in the vitreous of patients with proliferative vitreoretinopathy and proliferative diabetic retinopathy. Retina. 1998;18:546-550.
13. Elner SG, Elner VM, Jaffe GJ, Stuart A, Kunkel SL, Strieter RM. Cytokines in proliferative diabetic retinopathy and proliferative vitreoretinopathy. Curr Eye Res. 1995;14:1045-1053.
14. Abu El-Asrar AM, Van Damme J, Put W, et al. Monocyte chemotactic protein-1 in proliferative vitreoretinal disorders. Am J Ophthalmol. 1997;123:599-606.
15. Mitamura Y, Takeuchi S, Yamamoto S, et al. Monocyte chemotactic protein-1 levels in the vitreous of patients with proliferative vitreoretinopathy. Jpn J Ophthalmol. 2002;46:218-221.
16. El-Ghrably IA, Dua HS, Orr GM, Fischer D, Tighe PJ. Intravitreal invading cells contribute to vitreal cytokine milieu in proliferative vitreoretinopathy. Br J Ophthalmol. 2001;85:461-470.
17. Banerjee S, Savant V, Scott RAH, Curnow SJ, Wallace GR, Murray PI. Multiplex bead analysis of vitreous humor of patients with vitreoretinal disorders. Invest Ophthalmol Vis Sci. 2007;48:2203-2207.
18. Kauffmann DJH, Van Meurs JC, Mertens DAE, Peperkamp E, Master C, Gerritsen ME. Cytokines in vitreous humor: interleukin-6 is elevated in proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci. 1994;35:900-906.
19. La Heij EC, Van de Waarenburg MP, Blaauwgeers HG, et al. Basic fibroblast growth factor, glutamine synthetase, and interleukin-6 in vitreous fluid from eyes with retinal detachment complicated by proliferative vitreoretinopathy. Am J Ophthalmol. 2002;134:367-375.
20. Kon CH, Occleston NL, Aylward GW, Khaw PT. Expression of vitreous cytokines in proliferative vitreoretinopathy: a prospective study. Invest Ophthalmol Vis Sci. 1999;40:705-712.
21. Romano M, Sironi M, Toniatti C, et al. Role of IL-6 and its soluble receptor in induction of chemokines and leukocyte recruitment. Immunity. 1997;6:315-325.
22. Vignali DA. Multiplexed particle-based flow cytometric assays. J Immunol Methods. 2000;243:243-255.
23. De Jager W, Prakken BJ, Bijlsma JW, Kuis W, Rijkers GT. Improved multiplex immunoassay performance in human plasma and synovial fluid following removal of interfering heterophilic antibodies. J Immunol Methods. 2005;300:124-135.
24. Sijssens KM, Rijkers GT, Rothova A, et al. Cytokines, chemokines and soluble adhesion molecules in aqueous humor of children with uveitis. Exp Eye Res. 2007;85:443-449.
25. Retina Society Terminology Committee. The classification of retinal detachment with proliferative vitreoretinopathy. Am J Ophthalmol. 1983;90:121-125.
26. Dieudonné SC, La Heij EC, Diederen R, et al. High TGF-+2 levels during primary retinal detachment may protect against proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci. 2004;45:4113-4118.
27. De Jager W, Te Velthuis H, Prakken BJ, Kuis W, Rijkers GT. Simultaneous detection of 15 human cytokines in a single sample of stimulated peripheral blood mononuclear cells. Clin Diagn Lab Immunol. 2003;10:133-139.
28. Zlotnik A, Yoshie O. Chemokines: a new classification system and their role in immunity. Immunity. 2000;12:121-127.
29. Haelens A, Wuyts A, Proost P, et al. Leukocyte migration and activation by murine chemokines. Immunobiology. 1996;195: 499-521.
30. Nakazawa T, Hisatomi T, Nakazawa C, et al. Monocyte chemoattractant protein 1 mediates retinal detachment-induced photoreceptor apoptosis. Proc Natl Acad Sci USA. 2007;104:2425-2430.
31. Elner SG, Strieter RM, Elner VM, et al. Monocyte chemotactic protein gene expression by cytokine-treated human retinal pigment epithelial cells. Lab Invest. 1991;64:819-825.
32. Elner SG, Elner VM, Bian ZM, et al. Human retinal pigment epithelial cell interleukin-8 and monocyte chemotactic protein-1 modulation by T-lymphocyte products. Invest Ophthalmol Vis Sci. 1997; 38:446-455.
33. Han QH, Hui YN, Du HJ, Zhang WJ, Ma JX, Wang SY. Migration of retinal pigment epithelial cells in vitro modulated by monocyte chemotactic protein-1: enhancement and inhibition. Graefes Arch Clin Exp Ophthalmol. 2001;239:531-538.
34. Osusky R, Ryan SJ. Retinal pigment epithelial cell proliferation: potentiation by monocytes and serum. Graefes Arch Clin Exp Ophthalmol. 1996;234;(suppl 1):S76-S82.
35. Baggiolini M, Clark-Lewis I. Interleukin-8, a chemotactic and inflammatory cytokine. FEBS Lett. 1992;307:97-101.
36. Goczalik I, Ulbricht E, Hollborn M, et al. Expression of CXCL8, CXCR1, and CXCR2 in neurons and glial cells of the human and rabbit retina. Invest Ophthalmol Vis Sci. 2008;49:4578-4589.
37. Farber JM. Mig and IP-10: CXC chemokines that target lymphocytes. J Leukoc Biol. 1997;61:246-257.
38. Chen J, Vistica BP, Takase H, et al. A unique pattern of up- and down-regulation of chemokine receptor CXCR3 on inflammationinducing Th1 cells. Eur J Immunol. 2004;34:2885-2894.
39. Ohta K, Yamagami S, Wiggert B, Dana MR, Streilein JW. Chemokine gene expression in iris-ciliary body during experimental autoimmune uveoretinitis. Curr Eye Res. 2002;24:451-457.
40. Abu El-Asrar AM, Struyf S, Al-Kharashi SA, Missotten L, Van Damme J, Geboes K. The T-lymphocyte chemoattractant Mig is highly expressed in vernal keratoconjunctivitis. Am J Ophthalmol. 2003; 136:853-860.
41. Hooks JJ, Nagineni CN, Hooper LC, Hayashi K, Detrick B. IFN-β provides immuno-protection in the retina by inhibiting ICAM-1 and CXCL9 in retinal pigment epithelial cells. J Immunol. 2008; 180:3789-3796.
42. Iellem A, Mariani M, Lang R, et al. Unique chemotactic response profile and specific expression of chemokine receptors CCR4 and CCR8 by CD4(_)CD25(_) regulatory T cells. J Exp Med. 2001; 194:847-853.
43. Kang S, Xie J, Ma S, Liao W, Zhang J, Luo R. Targeted knock down of CCL22 and CCL17 by siRNA during DC differentiation and maturation affects the recruitment of T subsets. Immunobiology. 2010;215:153-162.
44. Hieshima K, Imai T, Baba M, et al. A novel human CC chemokine PARC that is most homologous to macrophage-inflammatory protein-1α/LD78α and chemotactic for T lymphocytes, but not for monocytes. J Immunol. 1997;159:1140-1149.
45. Luzina IG, Papadimitriou JC, Anderson R, Pochetuhen K, Atamas SP. Induction of prolonged infiltration of T lymphocytes and transient T lymphocyte-dependent collagen deposition in mouse lungs following adenoviral gene transfer of CCL18. Arthritis Rheum. 2006;54:2643-2655.
46. De Vos AF, Hoekzema R, Kijlstra A. Cytokines and uveitis, a review. Curr Eye Res. 1992;11:581-597.
47. Yoshimura T, Sonoda KH, Sugahara M, et al. Comprehensive analysis of inflammatory immune mediators in vitreoretinal diseases. PLoS ONE. 2009;4:e8158.
48. La Heij EC, Van de Waarenburg MP, Blaauwgeers HG, et al. Levels of basic fibroblast growth factor, glutamine synthetase, and interleukin-6 in subretinal fluid from patients with retinal detachment. Am J Ophthalmol. 2001;132:544-550.
49. Fan W, Zheng JJ, Peiper SC, McLaughlin BJ. Changes in gene expression of ARPE-19 cells in response to vitreous treatment. Ophthalmic Res. 2002;34:357-365.
50. Yoshida A, Elner SG, Bian ZM, Kunkel SL, Lukacs NW, Elner VM. Differential chemokine regulation by Th2 cytokines during human RPE-monocyte coculture. Invest Ophthalmol Vis Sci. 2001;42: 1631-1638.
51. Hollborn M, Enzmann V, Barth W, Wiedemann P, Kohen L. Changes in the mRNA expression of cytokines and chemokines by stimulated RPE cells in vitro. Curr Eye Res. 2000;20:488-495.
52. Yoshida A, Elner SG, Bian ZM, Elner VM. Induction of interleukin-8 in human retinal pigment epithelial cells after denuding injury. Br J Ophthalmol. 2001;85:872-876.